Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Clinical trial NCT03801434 · RECRUITING

Trial details

NCT number: NCT03801434
Sponsor: William Shomali
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

BCR-JAK2 Fusion Protein Expression Blasts 20 Percent or Less of Peripheral Blood White Cells Blasts More Than 5 Percent of Bone Marrow Nucleated Cells Blasts More Than 5 Percent of Peripheral Blood White Cells Blasts Under 20 Percent of Bone Marrow Nucleated Cells Chronic Eosinophilic Leukemia, Not Otherwise Specified Eosinophilia Hepatomegaly Hypereosinophilic Syndrome JAK2 Gene Mutation Splenomegaly TEL-JAK2 Fusion Protein Expression

Start date: 2019-11-15
Primary completion: 2028-12-30
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.